B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy - Polvere, Jacopo; Fabbiani, Massimiliano; Pastore, Gabiria; Rancan, Ilaria; Rossetti, Barbara; Durante, Miriam; Zirpoli, Sara; Morelli, Enrico; Pettini, Elena; Lucchesi, Simone; Fiorino, Fabio; Tumbarello, Mario; et al. (medRxiv, 2022)
Background SARS-CoV-2 mRNA vaccines have demonstrated high immunogenicity in healthy subjects and preliminary results for people living with HIV (PLWHIV) are promising too. We have previously reported the persistence of spike-specific circulating IgG and memory B cells in healthy adults up to six months after mRNA SARS-CoV-2 vaccination. Unfortunately, limited longitudinal data are available for PLWHIV and no evidence of persistent spike-specific B cells have been reported yet.Methods We investigated the humoral response and the persistence of spike-specific memory B cells up to six months after vaccination with two doses of mRNA vaccines in 84 PLWHIV under ART and compared them to healthy controls (HCs). Humoral response was analyzed with enzyme-linked immunosorbent assay and with an angiotensin-converting enzyme 2 (ACE2) and receptor binding domain (RBD) inhibition assay. PBMCs were analyzed with a cytofluorimetric approach for B cell phenotyping.Findings Spike-specific IgG peaked 1 month after second dose and persisted up to six months after vaccination with no significant differences compared to HCs. The stratification of patients according to CD4+ T cell count showed a significantly lower IgG response in case of CD4<350/µl, remarking the relevance of immune reconstitution. The ability of IgG of blocking the binding between ACE2 and RBD was detected in 58·4% of PLWHIV, compared to 86·2% in HCs. The amount of circulating spike-specific memory B cells detected in PLWHIV six months after vaccination was not significantly different from HCs, while there was prevalence of antigen-specific double negative (IgD-/CD27-) cells, compared to controls.Interpretation In conclusion, the majority of PLWHIV developed spike-specific humoral and B cell responses that persist for at least six months after SARS-CoV-2 mRNA vaccination. However, hints of HIV-dependent immune impairment were revealed by altered spike-specific B cell phenotypes and by reduced spike-specific humoral response in patients with low CD4+ T cell count (<350/µl).Competing Interest StatementMF received speakers honoraria, support for travel to meetings, and/or fees for attending advisory boards from Bristol Myers Squibb (BMS), Gilead, Janssen-Cilag, Merck Sharp and Dohme (MSD), and ViiV Healthcare. FM received support for travel to meetings from Angelini, she is principal investigator in sponsor study by TLS (Toscana Life Science) and by GSK Vaccine SRL and she is the contact person for a service contract between GSK Vaccine SRL and Department of Medical Biotechnologies, University of Siena, without receiving any personal remuneration. The other authors declare no conflict of interest regarding this study.Funding StatementThis study was supported by the Department of Medical Biotechnologies of the University of Siena (D.M.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee for Clinical experimentation of Regione Toscana Area Vasta Sud Est (CEASVE) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data that underlie the results reported in this article, after de-identification, are available upon reasonable request to the authors